Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

The Impact of Ventilator Synchrony on Muscle Relaxant Consumption and Surgeon Satisfaction During Laparoscopic Cholecystectomy.

9 giugno 2026 aggiornato da: Hitham Mohammed Aly Elsayed

The goal of this clinical trial is to investigate the Impact of adding SIMV Synchronization to our standard PCV-VG mode of ventilation on muscle relaxant consumption, the frequency of relaxant top-ups and surgeon satisfaction during Laparoscopic Cholecystectomy surgeries in ASA I&II. The main question it aims to answer is do Ventilator synchrony (PCV-VG+SIMV) reduces muscle relaxant consumption and improves surgeon satisfaction by minimizing the perception of inadequate paralysis?

Primary hypothesis: Ventilator synchrony (PCV-VG+SIMV) reduces muscle relaxant consumption and improves surgeon satisfaction by minimizing the perception of inadequate paralysis.

Primary outcome;

  1. Compare total intraoperative rocuronium consumption (mg/kg) between PCV-VG and PCV-VG + SIMV
  2. To determine the frequency of additional muscle relaxant requests

Panoramica dello studio

Descrizione dettagliata

Laparoscopic cholecystectomy creates significant physiological challenges due to CO₂ pneumoperitoneum, including 25-50% reduction in lung compliance, increased airway pressures, and cephalad diaphragm displacement [1,2]. Effective intraoperative management of mechanical ventilation is crucial in laparoscopic surgeries. These procedures often require adequate neuromuscular blockade to ensure optimal surgical conditions, minimize patient movement, and maintain a steady operative field (3). Pressure-Controlled Volume-Guaranteed (PCV-VG) mode of Ventilations is our institutional standard for laparoscopic cholecystectomy. PCV-VG is an innovative mode of ventilation that uses consistent tidal volume in a decelerating flow, without increasing airway pressures. PCV-VG offers the benefits of both VCV and PCV, while reducing the incidence of barotrauma, making it a safe ventilatory mode of choice in surgeries involving changes in respiratory dynamics. (4). However, during pneumoperitoneum, unsynchronized spontaneous breathing efforts provoke diaphragmatic movements that surgeons misinterpret as inadequate neuromuscular blockade, triggering unnecessary relaxant requests (5) which increase the risk of residual neuromuscular blockade, delayed recovery, and high healthcare costs (6,7). Adding synchronized ventilation modes, such as SIMV (Synchronized Intermittent Mandatory Ventilation), may mask partial paralysis by aligning with patient effort, reducing visible chest or diaphragmatic movements and enhance both patient safety and surgical access [5,8].

This study aims to investigate the Impact of adding SIMV Synchronization to our standard PCV-VG mode of ventilation on muscle relaxant consumption, the frequency of relaxant top-ups and surgeon satisfaction during Laparoscopic Cholecystectomy.

Laparoscopic cholecystectomy presents unique anesthetic challenges due to pneumoperitoneum-induced changes in respiratory mechanics. Recent literature has explored the role of ventilator modes, in influencing the need for neuromuscular blockade and surgeon satisfaction. Kim et al. (2020) demonstrated that PCV-VG improved gas exchange and respiratory compliance compared to traditional volume-controlled ventilation during laparoscopic surgery [1]. Similarly, Sukriti et al. (2023) found PCV-VG superior to both pressure-controlled and volume-controlled modes in maintaining better respiratory dynamics in laparoscopic cholecystectomy patients [4]. Furthermore, Park et al. (2022) highlighted how pneumoperitoneum alters thoracic compliance and increases the work of breathing. Their findings underscore the importance of tailored ventilator strategies that optimize patient-ventilator synchrony during laparoscopy [2].

A systematic review by Bruintjes et al. (2017) confirmed that deep NMB enhances laparoscopic surgical conditions and may improve surgeon satisfaction [3]. However, Brull and Murphy (2010) emphasized that deeper paralysis may increase the risk of residual neuromuscular blockade postoperatively if not properly monitored and reversed.[6] Ventilator-patient asynchrony may increase the requirement for both sedatives and neuromuscular blockers. De Wit et al. (2011) demonstrated that ineffective triggering during mechanical ventilation was associated with increased use of neuromuscular blockers [7]. Thus, synchronized modes that accommodate patient effort might reduce the need for deep muscle relaxation.

The most recent narrative review by Santana et al. (2024) reinforces the importance of individualized ventilator strategies during laparoscopic and robotic surgeries. The authors argue for the use of lung-protective ventilation and synchronization to enhance both patient safety and surgical access [5].

In summary, literature supports the concept that synchronized ventilator modes may reduce muscle relaxant consumption and improve surgeon satisfaction by optimizing respiratory mechanics and minimizing patient-ventilator asynchrony. Combined with appropriate neuromuscular monitoring and individualized ventilation strategies, these can enhance both laparoscopic surgical conditions and surgeon satisfaction ( 2.3) Knowledge Gaps

No previous studies have examined:

  • Interaction between ventilator synchrony and NMB requirements.
  • Impact of asynchrony on surgeon satisfaction metrics.
  • Relaxant-sparing effects of optimized ventilation 3- Hypothesis

    • Ventilator synchrony (PCV-VG+SIMV) reduces muscle relaxant consumption and improves surgeon satisfaction by minimizing the perception of inadequate paralysis.

      4- Objectives

    • Primary Objective.

      1. Compare total intraoperative rocuronium consumption (mg/kg) between PCV-VG and PCV-VG + SIMV
      2. To determine the frequency of additional muscle relaxant requests
    • Secondary Objectives.

      1. Surgical Conditions Assessement via Leiden-Surgical Rating Scale (Martini et al., 2014) (10)
  • 1 = Extremely poor conditions
  • 2 = Poor conditions
  • 3 = Acceptable conditions
  • 4 = Good conditions
  • 5 = Optimal conditions 2. Residual Paralysis: TOF ratio <0.9 at PACU admission (Naguib et al., 2017) (11) 3. Ventilatory Mechanics: Peak pressure, dynamic compliance, PaO₂/FiO₂ 4. Recovery Metrics: Extubation time, PACU discharge readiness (Aldrete ≥9) (12) 5- Intraoperative complications or Challenges (gallbladder, bowel or vascular injuries, need for high insufflation pressure. Difficulty in gallbladder extraction or the need for extra trocar ports 5. Hemodynamics: MAP, HR, vasopressor requirements. 5- Methodology 5.1 Study Design

    • Prospective randomized, double-blind, two parallel-groups controlled trial
    • Setting: Operating rooms in King Fahad university Hospital
    • Duration: Two years 5.2 Population Inclusion Criteria
  • Adults aged 18-60 years undergoing elective laparoscopic cholecystectomy.
  • ASA (American Society of Anesthesiologists) physical status I-II
  • BMI 18-35 kg/m² Exclusion Criteria
  • Severe COPD or restrictive lung disease
  • Neuromuscular disorders
  • Emergency surgery
  • Morbid obesity 5.3 Randomization Patients will be randomly assigned to either the synchronized or non-synchronized ventilation group using a computer-generated sequence.

5.4 Blinding: There will be three group: group one (the anesthesiologist who will perform anesthesia and respond to the surgical requests, group two (the anesthesiologist who will design the specific anesthetic plan, and ventilator sitting and the third group (the anesthesiologist who will collect the research data) both group one and three as well as the surgeon are blind to the study design and group assignment. The group two anesthesiologist will leave the room and will not attend the surgery.

5.5 Intervention Groups

  1. Non-Synchronized Group (Control): Ventilation managed using PCV-VG mode of ventilation.
  2. Synchronized Group: Ventilation managed using PCV-VG plus SIMV (a mixed mode that supports patient-ventilator synchrony).

5.6 Ventilator Settings • Both groups will follow institutional protocols for initial ventilator settings, adjusted for tidal volume (6-8 mL/kg), accustomed respiratory rate, to maintain intraoperative normocapnia (EtpCO2 = 35-45 mmHg), PEEP = 5 cm H₂O, FiO2 =30-40%

5.7 Anesthesia Protocol

  • Induction: Standardized use of propofol (2-2.5 mg/kg), and fentanyl (2mcg/kg) and an initial dose of rocuronium (0.6mg/kg).
  • Maintenance: Balanced anesthesia with inhalational agents Sevoflurane (1.0 MAC)) and fentanyl infusion (1-2 mcg /kg/hr).
  • Rocuronium top-up doses (0.1 mg/kg) to maintain the recommended level of relaxation for laparoscopic surgery (TOF = 1-2 twitches) [3,9], or upon surgeon request.

    6-Data Collection Protocol

    1. Primary Outcome:

  • Total intraoperative muscle relaxant consumption (mg).
  • Number of surgeon request for rocuronium top-up (0.1 mg/kg) due to:

    1. Sustained diaphragmatic jerking (>5 sec) 2. Loss of surgical field exposure 3. Abdominal wall contraction 2. Secondary Outcomes:

  • TOF ratio; Base line, postintubation, every 15 mins., at the time of each muscle relaxant request, at the conclusion of surgery & before extubation.
  • Asynchrony Index (AI): (%) = (Ineffective efforts + Double-triggering) / Total breaths × 100' (continues)
  • Peak airway pressure /15 min
  • Compliance /15 min
  • Delivered tidal volume/15 min
  • Surgeon satisfaction scores (Likert scale: 1-5). (13)
  • Incidence of residual neuromuscular blockade (recurarization) in the PACU
  • Vital signs /15 min (HR. NIBP, RR, and EtpCO2)
  • Possible intraoperative complications or Challenges (gallbladder, bowel or vascular injuries, need for high insufflation pressure. Difficulty in gallbladder extraction or the need for extra trocar ports) 3. Patient demographics and surgical Data o Age, Sex, BMI, ASA status, and duration of surgery 7- Statistical Plan Sample Size Calculation If we assume the difference between the mean total dose of rocuronium between the control group and intervention group 35 mg., and a pooled standard deviation of 33 mg the study would require a sample size of 38 patients (19 patients for each group), to achieve a power of 90% and a level of significance of 5%. However, we will recruit 60 patients (30 in each group) in this study to compensate for any possible exclusion as well as to strengthen our ± statistical analysis.

Primary Outcome: Comparison of muscle relaxant consumption between groups using an independent t-test or Mann-Whitney U test (if non-normal distribution).

  • TOF Ratios: Analyzed using ANOVA for repeated measures.
  • Surgeon Satisfaction: Non-parametric tests (e.g., Wilcoxon rank-sum) for Likert scores.
  • Categorical data: Categorical data: Chi-square/Fisher's exact
  • Multivariate Analysis: for vital signs 8. Ethical Considerations

    • Approval: Institutional Review Board (IRB)
    • Consent: Written informed consent (Declaration of Helsinki)
    • Data Safety: Anonymized storage.

      9. Expected Outcomes & Impact

    • Anticipated Findings:
    • 20-25% reduction in rocuronium with PCV-VG+SIMV
    • Equivalent surgical conditions (Leiden scale ≥4/5)
    • Lower residual paralysis (TOF <0.9 in 10% vs. 25%)
    • Clinical Implications:
    • Reduced NMB drugs & related complications
    • Cost savings from lower drug use
    • Protocol for optimized ventilation in laparoscopy 9. Limitations
    • Single-center design
    • Surgeon subjectivity in Leiden scoring
    • Generalizability to morbid obesity (BMI >35 excluded)

Tipo di studio

Interventistico

Iscrizione (Stimato)

60

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

  • Nome: Roshdi M Almetwalli, MD
  • Numero di telefono: 1486 009660138966666
  • Email: rmetwalli@iau.edu.sa

Luoghi di studio

    • Eastern Province
      • Khobar, Eastern Province, Arabia Saudita, 34445
        • King Fahd University Hospital

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

  • Adulto

Accetta volontari sani

No

Descrizione

Inclusion Criteria:

  • Adults aged 18-60 years undergoing elective laparoscopic cholecystectomy.
  • ASA (American Society of Anesthesiologists) physical status I-II
  • BMI 18-35 kg/m²

Exclusion Criteria:

  • Severe COPD or restrictive lung disease
  • Neuromuscular disorders
  • Emergency surgery
  • Morbid obesity

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Altro
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Triplicare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Comparatore attivo: Non-Synchronized Group (Control)
Ventilation managed using PCV-VG mode of ventilation
Ventilation managed using PCV-VG mode of ventilation
Comparatore attivo: Synchronized Group
Ventilation managed using PCV-VG plus SIMV (a mixed mode that supports patient-ventilator synchrony)
Ventilation managed using PCV-VG plus SIMV (a mixed mode that supports patient-ventilator synchrony)

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Lasso di tempo
Total intraoperative muscle relaxant consumption
Lasso di tempo: during the surgery time 1 to 2 hours
during the surgery time 1 to 2 hours
Number of surgeon request to rocuronium top-up doses
Lasso di tempo: during time of surgery from 1 to two hours
during time of surgery from 1 to two hours

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Train of four (TOF) ratio
Lasso di tempo: during time of surgery from 1 to two hours
during time of surgery from 1 to two hours
Peak airway pressure
Lasso di tempo: during time of surgery from 1 to two hours
every 15 minutes
during time of surgery from 1 to two hours
Compliance
Lasso di tempo: during time of surgery from 1 to two hours
every 15 minutes
during time of surgery from 1 to two hours
Delivered tidal volume
Lasso di tempo: during time of surgery from 1 to two hours
every 15 minutes
during time of surgery from 1 to two hours
Surgeon satisfaction scores (Likert scale: 1-5)
Lasso di tempo: during time of surgery from 1 to two hours
during time of surgery from 1 to two hours
Incidence of residual neuromuscular blockade (recurarization)
Lasso di tempo: one hour after surgery
one hour after surgery
Vital signs (HR. NIBP, RR, SpO2%)
Lasso di tempo: during time of surgery from 1 to two hours
every 15 minutes
during time of surgery from 1 to two hours
intraoperative complications or Challenges (gallbladder, bowel or vascular injuries, need for high insufflation pressure. Difficulty in gallbladder extraction or the need for extra trocar ports)
Lasso di tempo: during time of surgery from 1 to two hours
during time of surgery from 1 to two hours
demographics and surgical Data (Age, Sex, BMI, ASA status, and duration of surgery)
Lasso di tempo: during time of surgery from 1 to two hours
during time of surgery from 1 to two hours

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

1 agosto 2026

Completamento primario (Stimato)

1 dicembre 2028

Completamento dello studio (Stimato)

1 giugno 2029

Date di iscrizione allo studio

Primo inviato

25 maggio 2026

Primo inviato che soddisfa i criteri di controllo qualità

9 giugno 2026

Primo Inserito (Effettivo)

15 giugno 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

15 giugno 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

9 giugno 2026

Ultimo verificato

1 giugno 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Descrizione del piano IPD

To protect patient privacy and confidentiality of data

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Prove cliniche su Non-Synchronized Group (Control)

Sottoscrivi